# Relypsa

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/relypsa/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | clinical trial |
| OpenAlex ID | https://openalex.org/F4320336263 |
| Works | 613 |

## Funder papers

Showing 15 of 16.

- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial](https://scholariq.org/papers/evaluation-of-the-efficacy-and-safety-of-rly5016-a-polymeric-potassium-binder-in/)
- [A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease](https://scholariq.org/papers/a-randomized-controlled-study-of-finerenone-vs-eplerenone-in-patients-with/)
- [Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/patiromer-versus-placebo-to-enable-spironolactone-use-in-patients-with-resistant/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-reducing-serum-potassium-and-preventing-recurrent/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study](https://scholariq.org/papers/the-effect-of-intravenous-ferric-carboxymaltose-on-health-related-quality-of/)
- [A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease](https://scholariq.org/papers/a-comparative-post-hoc-analysis-of-finerenone-and-spironolactone-in-resistant/)
- [Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial](https://scholariq.org/papers/effects-of-canagliflozin-on-cardiovascular-renal-and-safety-outcomes-in/)
- [Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial](https://scholariq.org/papers/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/)
- [Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure](https://scholariq.org/papers/patiromer-versus-placebo-to-enable-spironolactone-use-in-patients-with-resistant-2/)
- [Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-hyperkalemia-recurrence-in-older-chronic-kidney-disease/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.